Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 243 results found since Jan 2013.
CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day.
The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
M024 don ’t stop hpv vaccine with one dose left, go see an allergist!
HPV is the most common sexually transmitted infection in the US. HPV is associated with cervical, vulvar, and vaginal cancer in females, penile cancer in males, and anal and oropharyngeal cancer in both females and males. FDA-approved in 2014, human papillomavirus vaccine (9vHPV, Merck), aids in the prevention of diseases caused by nine types of HPV. 9vHPV is now licensed in the US for females and males ages 9 through 45 years. For those 15 years and older, a 3-dose schedule is recommended.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: M. Lukas, M. Tankersley Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Development and validation of a tool for evaluating YouTube-based medical videos
ConclusionCollectively, our findings indicated that the MQ-VET is a valid and reliable tool that will help to standardize future evaluations of online medical videos.
Source: Irish Journal of Medical Science - November 25, 2021 Category: General Medicine Source Type: research
NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2022 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIH & NIDCR Release “Oral Health in America: Advances and Challenges”
In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news
Defining the risk of SARS-CoV-2 variants on immune protection
We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.PMID:35361968 | DOI:10.1038/s41586-022-04690-5
Source: Cancer Control - April 1, 2022 Category: Cancer & Oncology Authors: Marciela M DeGrace Elodie Ghedin Matthew B Frieman Florian Krammer Alba Grifoni Arghavan Alisoltani Galit Alter Rama R Amara Ralph S Baric Dan H Barouch Jesse D Bloom Louis-Marie Bloyet Gaston Bonenfant Adrianus C M Boon Eli A Boritz Debbie L Bratt Traci Source Type: research
Novel COVID-19 Vaccine for Patients With Blood Cancers Novel COVID-19 Vaccine for Patients With Blood Cancers
A novel vaccine (CoVac-1) currently in clinical trials in Germany induced T-cell immune responses in a large proportion of patients with blood cancers and B cell deficiencies.Medscape Medical News
Source: Medscape Allergy Headlines - April 19, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Nanobodies Neutralizing Lassa Virus
Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- specific vaccines or therapies.Researchers ...
Source: NIH OTT Licensing Opportunities - April 26, 2022 Category: Research Authors: ott8admin Tags: Therapeutics Licensing Desired & Collaboration Desired Collaboration Sought NIAID NCI Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
News at a glance: China ’s carbon pledge, ARPA-H’s interim head, and an exascale computer
Some content has been removed for formatting reasons. Please view the original article for the best reading experience.
Table of contents
A version of this story appeared in Science, Vol 376, Issue 6597.
Download PDF
CONSERVATION
U.S. moves to stop Alaska copper mine
The U.S. Environmental Protection Agency (EPA) is moving to block construction of a massive copper and gold mine that would risk polluting the headwaters of Alaska’s Bristol Bay, home to the world’s largest sockeye salmon runs. EPA announced last week it plans to forbid dis...
Source: Science of Aging Knowledge Environment - June 2, 2022 Category: Geriatrics Source Type: research
SARS-CoV-2 omicron: Light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients?
J Allergy Clin Immunol Pract. 2022 Jun 22:S2213-2198(22)00597-9. doi: 10.1016/j.jaip.2022.06.011. Online ahead of print.ABSTRACTCOVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were at increased risk of severe disease. In addition, patients with some forms of immun...
Source: Clinical Lung Cancer - June 25, 2022 Category: Cancer & Oncology Authors: Rohan Ameratunga Euphemia Leung See-Tarn Woon Lydia Chan Richard Steele Klaus Lehnert Hilary Longhurst Source Type: research
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
Curr Opin Chem Biol. 2022 Jul 1;70:102172. doi: 10.1016/j.cbpa.2022.102172. Online ahead of print.ABSTRACTUntil recently, the development of new human adjuvants was held back by a poor understanding of their mechanisms of action. The field was revolutionized by the discovery of the toll-like receptors (TLRs), innate immune receptors that directly or indirectly are responsible for detecting pathogen-associated molecular patterns (PAMPs) and respond to them by activating innate and adaptive immune pathways. Hundreds of ligands targeting various TLRs have since been identified and characterized as vaccine adjuvants. This work...
Source: Current Opinion in Chemical Biology - July 5, 2022 Category: Biochemistry Authors: Arshpreet Kaur Jeremy Baldwin Deshkanwar Brar Deepak B Salunke Nikolai Petrovsky Source Type: research
